Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 15,394 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 15,394 shares of Tyra Biosciences stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $25.85, for a total transaction of $397,934.90. Following the completion of the transaction, the chief executive officer now owns 1,418,647 shares of the company’s stock, valued at $36,672,024.95. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Todd Harris also recently made the following trade(s):

• On Tuesday, October 15th, Todd Harris sold 10,035 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $243,950.85.
• On Monday, September 30th, Todd Harris sold 500 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.00, for a total transaction of $12,000.00.
• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total value of $14,406.00.
• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total value of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Price Performance

Shares of NASDAQ TYRA opened at $27.33 on Friday. The business has a 50-day moving average of $22.32 and a 200-day moving average of $19.49. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -16.17 and a beta of 1.01. Tyra Biosciences, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $27.55.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.09. On average, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Institutional Trading of Tyra Biosciences

A number of large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in shares of Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after purchasing an additional 8,324 shares during the period. Oppenheimer & Co. Inc. acquired a new position in Tyra Biosciences during the first quarter worth approximately $977,000. Vanguard Group Inc. increased its position in Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares during the last quarter. BVF Inc. IL raised its stake in Tyra Biosciences by 70.1% in the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after buying an additional 1,921,599 shares during the period. Finally, Kynam Capital Management LP lifted its position in shares of Tyra Biosciences by 51.4% in the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock valued at $8,449,000 after buying an additional 175,000 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Oppenheimer lifted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. HC Wainwright upped their price target on Tyra Biosciences from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Piper Sandler started coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $22.00 to $31.00 in a report on Friday. Finally, Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Thursday, August 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.00.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.